CNBS

Amplify Seymour Cannabis ETF

As of 3/31/24

FUND FACTS

Ticker	CNBS
CUSIP	032108854
Inception Date	07/23/2019
Primary Exchange	NYSE ARCA
Number of Holdings	28

FEES & EXPENSES

Management Fee	0.65%
Other Expenses	0.78%
Total Annual Fund Operating Expenses	1.45%
Less Fee Waiver/Reimbursement*	0.68%
Net Expense Ratio	0.77%

PORTFOLIO MANAGEMENT



Tim Seymour Seymour Asset Management LLC

MARKET CAPITALIZATION

Large Cap (> \$10B)	0.00%
Mid Cap (\$2B - \$10B)	41.00%
Small Cap (< \$2B)	59.00%

ACTIVELY MANAGED BY CANNABIS INVESTMENT PROFESSIONAL TIM SEYMOUR

CNBS is an ETF investing in the fast developing global cannabis industry. The Fund will hold a basket of companies diversified by industry, market cap and business focus, which helps to mitigate single stock risk.

REASONS TO INVEST

- (1) **Consumer Demand** Global spending on legal cannabis nearly doubled growing from \$14.9 billion in 2019 to \$30 billion in 2021.^{1,2}
- (2) Legalization Currently legal in some form in 47 US states and 21 countries, with more anticipated to come.
- 3 Medical Use Over 100 naturally occurring compounds cannabinoids are found in the cannabis plant. Currently three FDA approved drugs exist that incorporate cannabis compounds; however, research into other use and application cases is dramatically increasing.

TOP 10 HOLDINGS

TICKER	COMPANY	% WT.	TICKER	COMPANY	% WT.
TRUL CN	Trulieve Cannabis Swap	14.07%	CL CN	Cresco Labs Swap	6.50%
GTII CN	Green Thumb Industries Swap	13.70%	IIPR	Innovative Indl Pptys Inc	5.11%
CURA CN	Curaleaf Hldgs Swap	10.08%	TSND CN	Terrascend Corp	4.93%
VRNO CN	Verano Hldgs Swap	9.28%	MAPS	WM Technology Inc	4.33%
TLRY	Tilray Brands Inc	7.73%	GRWG	GrowGeneration Corp	3.83%


Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

PERFORMANCE	CUMULATIVE (%)			ANNUALIZED (%)		
	1 MO.	YTD	SINCE INCEPTION	1 YR.	3 YR.	SINCE INCEPTION
Fund NAV	20.79%	34.62%	-76.29%	37.19%	-41.51%	-26.41%
Closing Price	19.46%	35.13%	-76.38%	37.04%	-41.65%	-26.47%

Fund inception date: 07/23/2019. The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end please visit **AmplifyETFs.com/CNBS**. Brokerage commissions will reduce returns. A fund's NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price or market price is the most recent price at which the fund was traded.

COUNTRY ALLOCATION

MARKET ALLOCATION





- MSO (49.36%)
- Cultivation & Retail (29.76%)
- Investing & Finance (6.56%)
- Real Estate (6.47%)
- Agricultural Technology (6.35%)
- Hemp Products (0.68%)
- Cannabis-Infused Products (0.47%)
- Pharmaceuticals/Biotechnology (0.35%)

ACTIVE MANAGEMENT SELECTION PROCESS

CNBS invests at least 80% of its assets in securities of companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem, across one of three classifications:

Cannabis/Hemp Plant

- Pharma/BioTech
- Cultivation & Retail
- Hemp Products
- Cannabis-infused Products

Support

- Agricultural Tech
- Real Estate
- Commercial Services

Ancillary

- Consumption Devices
- Investing & Finance
- Tech & Media

Carefully consider the Fund's investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund's statutory and summary prospectuses, which may be obtained at amplifyetfs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. The Fund is subject to management risk because it is an actively managed. Companies involved in the cannabis industry face competition, may have limited access to the services of banks, may have substantial burdens on company resources due to litigation, complaints or enforcement actions, and are heavily dependent on receiving necessarypermits and authorizations to engage in medical cannabis research or to otherwise cultivate, possess or distribute cannabis. The possession and use of cannabis, even for medical purposes, is illegal under federal and certain states' laws, which may negatively impact the value of the Fund's investments. Securities issued by non-U.S. companies present risks beyond those of securities of U.S. issuers.

Many of the companies in which the Fund will invest are engaged in other lines of business unrelated to cannabis and these lines of business could adversely affect their operating results. Cannabis is a Schedule I controlled substance under the Controlled Substances Act ("CSA"), meaning that it has a high potential for abuse, has no currently "accepted medical use" in the U.S., lacks accepted safety for use under medical supervision, and may not be prescribed, marketed

or sold in the U.S. Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may be less liquid and may experience greater price volatility than larger, more established companies as a result of several factors, including limited trading volumes, products or financial resources, management inexperience and less publicly available information. The Fund is non-diversified, which can cause greater share price fluctuation.

Amplify Investments LLC is the Investment Adviser to the Fund. Seymour Asset Management LLC and Penserra Capital Management, LLC serve as the Investment Sub-Advisers. Amplify ETFs are distributed by Foreside Fund Services, LLC.

*The Fund's investment adviser has contractually agreed to waive its advisory fees and/or assume as its own expense certain expenses otherwise payable by the Fund to the extent necessary to ensure that total annual fund operating expenses do not exceed 0.75% of average daily net assets until March 1, 2025.

¹BDSA, Arcview Market Research.

²BDSA. Press Release. As of 9/13/2022. Trend of continued growth is not guaranteed.

Not FDIC Insured | No Bank Guarantee | May Lose Value